LOS ANGELES (Reuters) -Eisai and Biogen’s Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer’s treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The FDA decision marks a new milestone for a fatal…Read More
US FDA grants standard approval of EisaiBiogen Alzheimers drug
